WIXLIB

Nursing drug handbook pdf free downloadIn this post we have shared an overview and download link of Nurse’s Drug Handbook 2021 PDF. The Drug Guide for nurses & other clinicians is always dependable, always up to date The thoroughly updated Nurse’s Drug Handbook 2021. You must have this book on your study table if want to learn nursing thoroughly. Read the quick review belowand download the PDF by using links given at the end of the post. BOOK INFO : Book’s Name : Nurse’s Drug Handbook 2021 Edition : 20th edition 2021 Size : 38 MB Pages : 2901 Format : PDF (DIRECT LINK) Features Of Nurse’s Drug Handbook 2021 The Nurse’s Drug Handbook clearly and concisely presents all the vital facts on the drugs thatyou’ll typically administer. To help you find the information you need quickly, drug entries are organized alphabetically by generic drug name. For ease of use, every drug entry follows a consistent format. However, if specific details are unknown or don’t apply, the heading isn’t included so you can go right to the next section. First, each entryidentifies the drug’s main generic name, as well as alternate generic names. (For drugs prescribed by trade name, you can quickly check the comprehensive index, which refers you to the appropriate generic name and page.) CLASS, CATEGORY, AND SCHEDULE Each entry lists the drug’s pharmacologic and therapeutic classes. With thisinformation, you can compare drugs in the same pharmacologic class but in different therapeutic classes. This section concisely describes how a drug achieves its therapeutic effects at cellular, tissue, and organ levels, as appropriate. Illustrations of selected mechanisms of action lend exceptional clarity to sometimes complex processes. Analphabetical list details the conditions and disorders that preclude administration of the topic drug. This section includes drugs, foods, and activities (such as alcohol use and smoking) that can cause important, problematic, or life-threatening interactions with the topic drug. For each interacting drug, food, or activity, you’ll learn the effects of theinteraction. Organized by body system, this section highlights common, serious, and life-threatening adverse reactions. In short, the Nurse’s Drug Handbook is designed expressly to give you more of what you need. It puts vital drug information at your fingertips and helps you always stay current in this critical part of your practice or studies.DOWNLOAD Nurse’s Drug Handbook 2021 : Click Below to download nurse’s drug handbook for free. You May Missed : Search @eduwaves360 on telegram if link is not worked Disclaimer We, eduwaves360.com does no longer owns these books neither created nor scanned. We simply offer the hyperlink which already to be had on the internet. Ifany manner it violates the law or has any troubles, then kindly mail us: eduwaves360@gmail.com or Contact Us for this(hyperlink removal). We don’t aid piracy; this grows to supply for educational purpose only. Thank you. Heparin Hydrocortisone Hydromorphone Imipenem Insulin Labetalol Levofloxacin Linezolid Lorazepam Magnesium MannitolMeropenem Methylprednisolone Metoclopramide Metronidazole Midazolam Morphine Nicardipine Nitroglycerin Nitroprusside Norepinephrine Octreotide Ondansetron Pantoprazole Phenylephrine Piperacillin/Tazobactam Potassium Chloride Propofol Sodium Bicarbonate Tigecycline Tobramycin Vancomycin Vasopressin C C I I N N C C N C N N C C IN C N C C I N N N N I N C C N C N C N C N N N C N N N N N I N C C N N N N N N N C C N C N N N C N C N C N C C N I C C N C N I C N C N C N N C C N N N N N N C N C C N C C C C C N N C I N C I C N I N N N N N C C N N N C N N C C C N N N N N C N C N N N N N N N C C C N N N N N C N C C N C N N N C I C N Gentamicin C I N NN N C N N C C I C C N N C N C C N C C C C C N C C C C I N Furosemide C C C C N I C C I C N C C N C N C N C C C C C C C N N C C C C C N Fluconazole I N I C N I C C C C N N N N N N C N C C N C I C C N N N I C C N C Famotidine N N C C C N N C N N N N N N N N N N C C N N N N N N N N C N I N N Esmolol N I I C N N I N N I C N C C IN N N N N N I I C N I N I N I C N N Eptifibatide I C N N N C C N N N C N C N N N C N C C N C N C N N N N N C C C N Epinephrine N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N Enalapril N C C C C N N C N C N N C N C N N N N C C N C C N C N C C N C N N Dopamine N N I N C N N C N N N N N N N N N N N CC N C C C C N C C N C N N Dobutamine N N C N C N N C N N N N N N N N N N N C C N C C C C N C C C I N N Diphenhydramine N C N N N N C N N C C I N N N N C N N N C N C C C C N C C N I C N Diltiazem C C C C C I C C C N C C C C N N C N C C C C C C C C N C C C C C C Dexmedetomidine N C C C C N N C I C C I C N C N C N I C C CC C N C N N C C C C N Dexamethasone C N N C N N I C N N C C C N C N N N N C C N N C C N N C N C N N C Daptomycin C N N N N N C C N I N N C N C N C N C C C C N N N N N N C C I N C Clindamycin C N C C N N C C N I N C C N I N C N N C I N N C C N N N C N N N C Ciprofloxacin I N N C N N N N N C N N N N N N N N C N N C N NC N N N N C C C N Ceftriaxone N C N N N N C C N N N N C N N N N N N N N N N N N N N N N N C N N Ceftaroline Fosamil C C I N N N C C N C C N C N I N C N N C N N C N C N N C C N N C C Cefepime C C C N N N I C C N N N C N C N N N C C C N C C N C N N C C C C C Cefazolin C C N C N N C N N C C N N C C N C N C C N C C C C NN C C N C C C Calcium Gluconate I C N C N I N C N N N N C N N N C C C C N N C C N C N N N N I C N Bumetanide N C C N N N N C N C C N I I N N C N N C C N C C C C N C C N I C N Bivalirudin N N C N N N C N N N C C C N N N N N N N N N C I N N N C C N N C N Aztreonam C N I C N I C N N N N N N N N N N N N N C C N N N N N N CI N N C Azithromycin C C N N N N C C N N I N C N N N C N C C C C C C N C N N C N C C C Argatroban C C N C C N C C N C N N C N I N C N C N C N N C C C N C C N C N C Anidulafungin C I I C N N C C N C C C C C I N C C C C C C C C C C N C C C C I C Amiodarone C — C N C N N I N N N C N C C N C N C N I C I I N N N N C C N C C C C NNNNC—ICCCNCCC C I C C C C N C C N I N N N C I N I I N C N I C I — I C C C N C C N I C C N N I C C N C C C N C C N N N C N N C C C I — C C C C N N N N C N C C C C C C C C N C C N C C C C N N N C C C C — Amikacin C C C C C C C C C C C C C C C C C I C C C C C C C C C C C C C C C Acyclovir Granisetron Acyclovir Amikacin Amiodarone AnidulafunginArgatroban Azithromycin Aztreonam Bivalirudin Bumetanide Calcium Gluconate Cefazolin Cefepime Ceftaroline Fosamil Ceftriaxone Ciprofloxacin Clevidipine Clindamycin Daptomycin Dexamethasone Dexmedetomidine Diltiazem Diphenhydramine Dobutamine Dopamine Enalapril Epinephrine Eptifibatide Esmolol Famotidine Fluconazole FurosemideGentamicin Granisetron Sodium Chloride C Physically compatible via Y-site administration. I Physically incompatible. N Information on compatibility not available or conflicting The IV compatibility table provides data when 2 or more medications are given in a Y-site of adminis tration. The data in this table largely represent physical incompatibilities(e.g., haze, precipitate, change in color). Therapeutic incompatibilities have not been included, so when using the table, professional judgement should be exercised. Dextrose 5% IV Compatibilities Granisetron C C C C C C N C C C N N C C N C C C C C C N C N C I C C C N N C N C N N I N N N N C N N C N C C C C N C N N N C I N C C C N C C C CNCCNCNCNNNNNCCCNNNNNNNININ C — N N C I N C N C C C C C C N C N N N C C C N N N N C I N I N C C C N — N N C N N C C N N C N N N C N N C N N N C N C N N C C C N N C N N N — Vasopressin Gentamicin C C N N C C N C N C N N N N C N C C C C C N N I N N C C C N C C N Vancomycin Furosemide N N N N N N N N N N N N N N N N N N N N N N N N N N N N NN N N N Tobramycin Fluconazole C C C N N C C N C N N N N N N C C C C C C N N I N N N C I C N N C Tigecycline Famotidine Sodium Bicarbonate Esmolol C C N N N C N C N C N C C N C N C C C C N N N N N C C C N N N C N Propofol Eptifibatide C C C N I C C C C N N N C N C C C C C C C N C C N C C C N C N N C Potassium ChlorideEpinephrine Piperacillin/Tazobactam Enalapril C N C N C C C C C C N N N N N C C C C C C N N I N I C C N C N N C Phenylephrine Dopamine C N C C N N N C N N N C N C N C C N N N N N C I N C C C N N N N N Pantoprazole Dobutamine C C C C N C N N C N N N I C C C C C C C C N N N N N C N I N C C C Ondansetron Diphenhydramine C NC N N C C C C C N N C C C C C N C C C N C N C C C C C N C C N Octreotide Diltiazem C C C N N N C C C N N C N C N I C N N N N N C I N C C C C N N N N Norepinephrine Dexmedetomidine C N N N N N C N N N N N N N N N N N N N N N N N N N N N N N N N N Nitroprusside Dexamethasone C C C N N C C C N C N N C C N C C C N N NN C N N C C C C N C N N Nitroglycerin Daptomycin I I N N N N N C C I N N I C C C N N N N C N N I N N C N I C C N C Nicardipine Clindamycin C N N N N I N C N N N N N N N N C N N N N N N C N N N C C C N I N Morphine Ciprofloxacin C C C N C I C N C C C N C C C C C N N N C N C C N N C C C N C N C Midazolam Ceftriaxone C N N NC N N N N N N N C N C I C I N N N N N N N N C I N I I C N Metronidazole Ceftaroline Fosamil C N I N C C N C N C N N N N C C C C N N N N C C N N N C N N N I N Metoclopramide Cefepime C C N N N C N C N C N C I I N C N C N N C N N I N C C C C N C C N Meropenem Cefazolin N N N N N N N N C N N N N N N I C N N N N N N N N C NC N N N N N Mannitol Calcium Gluconate C C C N N C C N C C C N C C C C C N C C C N N N C C C N C N C I N Magnesium Bumetanide C C C C C N N C I C C N C C I N C C N N N N C I N C C C C N C C N Lorazepam Bivalirudin N N N I N N I N N N N N N N N N I N N N N N C N N I I N N C I N N Linezolid Aztreonam N C N N N N N N N N NN N N N C C N C C C N N N C N N N N N N N C Levofloxacin Azithromycin C C N C N N C C N N N C C N C C C N N N C N N C C C C N I N C C N Labetalol Argatroban I N N I C C N N C I N N C N N C C N C I C N N I C I C N I N C C C Insulin Anidulafungin I C C N N C C C C C C N N N N C C C N N C N C I N N C I C C N C N ImipenemAmiodarone C C C C N N I C C C N I C C C N C N N N N N I N N I C C C N C C N Hydromorphone Amikacin C C C C C C C C C C — C C C — C C C C C C C C C C C C C C C C C C Hydrocortisone Acyclovir C C C C N C C C N C — N C C — C C C C C C C C C C C C C C C C C — Heparin Sodium Chloride Heparin Hydrocortisone HydromorphoneImipenem Insulin Labetalol Levofloxacin Linezolid Lorazepam Magnesium Mannitol Meropenem Methylprednisolone Metoclopramide Metronidazole Midazolam Morphine Nicardipine Nitroglycerin Nitroprusside Norepinephrine Octreotide Ondansetron Pantoprazole Phenylephrine Piperacillin/Tazobactam Potassium Chloride Propofol SodiumBicarbonate Tigecycline Tobramycin Vancomycin Vasopressin Dextrose 5% C Physically compatible via Y-site administration. I Physically incompatible. N Information on compatibility not available or confl icting The IV compatibility table provides data when 2 or more medications are given in a Y-site of adminis tration. The data in this table largelyrepresent physical incompatibilities (e.g., haze, precipitate, change in color). Therapeutic incompatibilities have not been included, so when using the table, professional judgement should be exercised. Methylprednisolone IV Compatibilities Lifespan Considerations in each monograph note factors to be considered for geriatric, pediatric, pregnant, ornursing populations. Appendix G provides additional resources. Black Box Alerts advise about the increased risks of a particular drug. panitumumab 2 panitumumab pan-i-toom-ue-mab (Vectibix) BLACK BOX ALERT 90% of pts experience dermatologic toxicities (dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, skin fissures, abscess).Severe infusion reactions (anaphylaxis, bronchospasm, fever, chills, hypotension), fatal reactions have occurred. Interactions identify potential herbal, drug, and food interactions with a particular drug. CLASSIFICATION PHARMACOTHERAPEUTIC: Epidermal growth factor receptor (EGFR) inhibitor, monoclonal antibody. CLINICAL: Antineoplastic.LIFESPAN CONSIDERATIONS Pregnancy/Lactation: May cause fetal harm. May impair fertility. May decrease fetal body weight, increase risk of skeletal fetal abnormalities. Use effective contraception during and for at least 6 mos after treatment. Breastfeeding not recommended. Children: Safety and efficacy not established. Elderly: No age-relatedprecautions noted. INTERACTIONS DRUG: None significant. HERBAL: None significant. FOOD: None known. LAB VALUES: May decrease serum magnesium, calcium. AVAILABILITY (RX) Injection Solution: 20 mg/mL vial (5-mL, 20-mL vials). USES Treatment of wild-type RAS metastatic colorectal cancer either as first-line therapy in combinationwith FOLFOX or as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, or irinotecan-based regimens. PRECAUTIONS P Uses section in each monograph notes the standard and off-label uses for a particular drug. Contraindications: Hypersensitivity to panitumumab. Cautions: Interstitial pneumoni- tis,pulmonary fibrosis, pulmonary infiltrates, renal impairment, baseline electrolyte imbalance. Not indicated in pts with RAS-mutant metastatic colorectal cancer or for whom RAS mutation status is unknown. ACTION Binds specifically to epidermal growth factor receptor (EGFR) and competitively inhibits binding of epidermal growth factor. Blocksactivation of intracellular tyrosine kinase. Therapeutic Effect: Inhibits tumor cell growth, survival, and proliferation. PHARMACOKINETICS Clearance varies by body weight, gender, tumor burden. Half-life: 3–10 days. IV Incompatibilities present important information for IV drugs. ADMINISTRATION/HANDLING IV ALERT Do not give by IV push orbolus. Use low protein-binding 0.2- or 0.22-micron in-line filter. Flush IV line before and after chemotherapy administration with 0.9% NaCl. Reconstitution Dilute in 100–150 mL 0.9% NaCl to provide concentration of 10 mg/mL or less. Do not shake solution. Invert gently to mix. Discard any unused portion. Rate of Administration Give as IVinfusion over 60 min. Infuse doses greater than 1,000 mg over 90 min. Storage Refrigerate vials. After dilution, solution may be stored for up to 6 hrs at room temperature, up to 24 hrs if refrigerated. Discard if discolored, but solution may contain visible, translucent-to-white particulates (will be removed by in-line filter). IVINCOMPATIBILITIES Do not mix with dextrose solutions or any other medications. underlined – top prescribed drug Top prescribed drugs are underlined. panitumumab INDICATIONS/ROUTES/DOSAGE ALERT Stop infusion immediately in pts experiencing severe infusion reactions. Metastatic Colorectal Cancer IV Infusion: ADULTS, ELDERLY: 6mg/kg once q14 days as a single agent or in combination with FOLFOX (fluorouracil, leucovorin and oxaliplatin). Continue until disease progression or unacceptable toxicity. Dose Modification Infusion Reactions Mild to moderate reactions: Reduce infusion rate by 50% for remainder of infusion. Severe reactions: Discontinue infusion. Depending onseverity, consider permanent discontinuation. Skin Toxicity Side Effects section in each drug monograph specifies the frequency of particular side effects. For all CTCAE grade 3 skin toxicities, withhold treatment for 1–2 doses until improved to better than grade 3. Then, reduce dose as follows: First occurrence of CTCAE grade 3: Resume at samedose. Second occurrence of CTCAE grade 3: Reduce dose to 80% of initial dose. Third occurrence of CTCAE grade 3: Reduce dose to 60% of initial dose. Fourth occurrence of CTCAE grade 3: Permanently discontinue. NURSING CONSIDERATIONS BASELINE ASSESSMENT Assess serum magnesium, calcium prior to therapy, periodically duringtherapy, and for 8 wks after completion of therapy. Assess KRAS mutational status in colorectal tumors and confirm the absence of a RAS mutation. INTERVENTION/EVALUATION Assess for skin, ocular, mucosal, pulmonary toxicity; report effects. Median time to development of skin/ocular toxicity is 14–15 days; resolution after last dosing is 84 days.Monitor serum electrolytes for hypomagnesemia, hypocalcemia. Offer antiemetic if nausea/vomiting occurs. Monitor daily pattern of bowel activity, stool consistency. PATIENT/FAMILY TEACHING Dosage in Renal/Hepatic Impairment No dose adjustment. SIDE EFFECTS Common Adverse Reactions highlight the particularly dangerous side effects. 3rarely. Severe infusion reactions manifested as bronchospasm, fever, chills, hypotension occur rarely. Hypomagnesemia occurs in 39% of pts. Life-threatening and/or fatal bullous fasciitis, abscess, sepsis were reported. Severe dehydration and diarrhea may increase risk of acute renal failure. Exposure to sunlight may exacerbate skin toxicities. Maycause ocular toxicities including keratitis, ulcerative keratitis, corneal ulceration. (65%–57%): Erythema, acneiform dermatitis, pruritus. Frequent (26%– 20%): Fatigue, abdominal pain, skin exfolia- tion, paronychia (soft tissue infection around nailbed), nausea, rash, diarrhea, constipation, skin fissures. Occasional (19%–10%): Vomiting, acne, cough,peripheral edema, dry skin. Rare (7%–2%): Stomatitis, mucosal inflammation, eyelash growth, conjunctivitis, increased lacrimation. ADVERSE EFFECTS/TOXIC REACTIONS Do not have immunizations without physician’s approval (drug lowers resistance). Avoid contact with those who have recently received a live virus vaccine. Avoid crowds,those with infection. There is a potential risk for development of fetal abnormalities if pregnancy occurs; take measures to prevent pregnancy. Report skin reactions, including rash, sloughing, blisters, erosions. Report difficulty breathing, fever with cough, lung pain; may indicate life-threatening lung inflammation. Limit sun, UV exposure.Wear protective sunscreen, hats, and clothing while outdoors. Pulmonary fibrosis, severe dermatologic toxicity (complicated by infectious sequelae) occur Canadian trade name Non-Crushable Drug High Alert drug High Alert drugs are shaded in blue for easy identification. P YOU’VE JUST PURCHASED MORE THAN A TEXTBOOK! Evolve StudentResources for Kizior/Hodgson: Saunders Nursing Drug Handbook, 2020, include the following: 100 Most Common Medications cations Less Frequently Used Drugs Non-Crushable Drugs Orphan Drugs Signs and Symptoms of Electrolyte Imbalance QT-Interval Prolongation and Medication Safety Techniques of Medication AdministrationActivate the complete learning experience that comes with each NEW textbook purchase by registering with your access code at code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above. REGISTERTODAY! Place Sticker Here You can now purchase Elsevier products on Evolve! Go to evolve.elsevier.com/shop to search and browse for products. 2018v1.0 i Saunders NURSING DRUG HANDBOOK 2020 ROBERT J. KIZIOR, BS, RPh Department of Pharmacy Alexian Brothers Medical Center Elk Grove Village, Illinois Keith J. Hodgson, RN, BSN,CCRN Staff Nurse, Intensive Care Unit Former Staff Nurse, Emergency Department St. Joseph’s Hospital Tampa, Florida 3251 Riverport Lane St. Louis, Missouri 63043 SAUNDERS NURSING DRUG HANDBOOK 2020 ISBN: 978-0-323-66140-9 ISSN: 1098-8661 Copyright 2020 by Elsevier, Inc. All rights reserved. All rights reserved. No part ofthis publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and ourarrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Practitioners andresearchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, noresponsibility is assumed by Elsevier, authors, editors, or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence, or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Previous editions copyright 2019, 2018, 2017, 2016,2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998, 1997, 1996, 1995, 1994, 1993 by Elsevier Inc. All rights reserved. Executive Content Strategist: Sonya Seigafuse Content Development Manager: Lisa Newton Senior Content Development Specialists: Tina Kaemmerer, Charlene KetchumPublishing Services Manager: Catherine Jackson Senior Project Manager/Specialist: Carrie Stetz Design Direction: Bridget Hoette Printed in the United States of America Last digit is the print number: 9 8 7 6 5 4 3 2 1 CONTENTS DRUGS BY DISORDER DRUG CLASSIFICATIONS A–Z DRUG ENTRIES APPENDIXES A. Calculation ofDoses B. Controlled Drugs (United States) C. Wound Care D. Drugs of Abuse E. Equianalgesic Dosing F. Herbals: Common Natural Medicines G. Lifespan, Cultural Aspects, and Pharmacogenomics of Drug Therapy H. Normal Laboratory Values I. Drug Interactions J. Antidote/Reversal Agents K. Preventing Medication Errors and Improving MedicationSafety L. Parenteral Fluid Administration M. Common Terminology Criteria for Adverse Events (CTCAE) INDEX xiii 1C 1 1249 1249 1250 1251 1256 1263 1264 1271 1275 1277 1282 1287 1291 1294 1296 iii AUTHOR BIOGRAPHIES Robert (Bob) J. Kizior, BS, RPh Bob graduated from the University of Illinois School of Pharmacy and is licensed topractice in the state of Illinois. He has worked as a hospital pharmacist for more than 40 years at Alexian Brothers Medical Center in Elk Grove Village, Illinois—a suburb of Chicago. Bob is the Pharmacy Surgery Coordinator for the Department of Pharmacy, where he participates in educational programs for pharmacists, nurses, physicians, andpatients. He plays a major role in coordinating pharmacy services in the OR satellite. Bob is a former adjunct faculty member at William Rainey Harper Community College in Palatine, Illinois. An avid sports fan, Bob also has eclectic tastes in music that range from classical, big band, rock ‘n’ roll, and jazz to country and western. Bob spends much ofhis free time reviewing the professional literature to stay current on new drug information. Keith J. Hodgson, RN, BSN, CCRN Keith was born into a loving family in Chicago, Illinois. His mother, Barbara B. Hodgson, was an author and publisher of several medication products, and her work has been a part of his life since he was a child. By the timehe was 4 years old, Keith was already helping his mother with the drug cards by stacking the draft pages that were piled up throughout their home. Because of his mother’s influence, Keith contemplated becoming a nurse in college, but his mind was fully made up after he shadowed his sister in the Emergency Department. Keith received hisAssociates Degree in Nursing from Hillsborough Community College and his Bachelor of Science in Nursing from the University of South Florida in Tampa, Florida. Keith started his career in the Emergency Department and now works in the Trauma / Neurological/Surgical Intensive Care Unit at St. Joseph’s Hospital in Tampa, Florida. Keith’s favoriteinterests include music, reading, Kentucky basketball, and, if he gets the chance, watching every minute of the Olympic Games. iv REVIEWERS Jared Collette, PharmD James Graves, PharmD Pharmacist Belleville, Kansas Clinical Pharmacist University of Missouri Hospital Columbia, Missouri v CONSULTANTS* Katherine B. Barbee, MSN, ANP, F-NPC Kaiser Permanente Washington, District of Columbia Marla J. DeJong, RN, MS, CCRN, CEN, Capt Linda Laskowski-Jones, RN, MS, CS, CCRN, CEN Christiana Care Health System Newark, Delaware Jessica K. Leet, RN, BSN Wilford Hall Medical Center Lackland Air Force Base, Texas Cardinal Glennon Children’s Hospital St. Louis, Missouri DianeM. Ford, RN, MS, CCRN Denise Macklin, BSN, RNC, CRNI Andrews University Berrien Springs, Michigan President, Professional Learning Systems, Inc. Marietta, Georgia Denise D. Hopkins, PharmD Judith L. Myers, MSN, RN College of Pharmacy University of Arkansas Little Rock, Arkansas Health Sciences Center St. Louis University School ofNursing St. Louis, Missouri Barbara D. Horton, RN, MS Kimberly R. Pugh, MSEd, RN, BS Arnot Ogden Medical Center School of Nursing Elmira, New York Nurse Consultant Baltimore, Maryland Mary Beth Jenkins, RN, CCRN, CAPA Regina T. Schiavello, BSN, RNC Elliott One Day Surgery Center Manchester, New Hampshire Wills Eye HospitalPhiladelphia, Pennsylvania Kelly W. Jones, PharmD, BCPS Gregory M. Susla, PharmD, FCCM McLeod Family Medicine Center McLeod Regional Medical Center Florence, South Carolina National Institutes of Health Bethesda, Maryland *The authors acknowledge the work of the consultants in previous editions. vi ACKNOWLEDGMENTS I would liketo thank my co-author Bob Kizior for his knowledge, experience, support, and friendship. We would like to give special thanks to Sonya Seigafuse, Charlene Ketchum, Carrie Stetz, Tina Kaemmerer, and the entire Elsevier team for their superior dedication, hard work, and belief in us. Without this wonderful team, none of this would be possible. KeithJ. Hodgson, RN, BSN, CCRN DEDICATION I dedicate my work to the practicing nurse, those aspiring to become nurses, and to all health care professionals who are dedicated to the art and science of healing. Bob Kizior, BS, RPh I dedicate this work to my sister, Lauren, a foundation for our family; my sister, Kathryn, for her love and support; myfather, David Hodgson, the best father a son could have; my brothers-in-law, Andy and Jim, great additions to the family; the grandchildren, Paige Olivia, Logan James, Ryan James, and Dylan Boyd; to Jen Nicely for always being there; and to my band of brothers, Peter, Jamie, Miguel, Ritch, George, Jon, Domingo, Ben, Craig, Pat, and Shay. We alsomake a special dedication to Barbara B. Hodgson, RN, OCN. She truly was a piece of something wonderful. Barbara often gave her love and support without needing any in return, and would do anything for a smile. Not only was she a colleague and a friend, she was also a small business owner, an artist, a dreamer, and an innovator. We hope thepride we offer in her honor comes close to what she always gave us. Her dedication and perseverance lives on. Keith J. Hodgson, RN, BSN, CCRN BIBLIOGRAPHY Lexi-Comp’s Drug Information Handbook, ed 27, Hudson, OH, 2018–2019, Lexi-Comp. Medical Letter on Drugs and Therapeutics: 2017–2018, Pharmacists Letter: 2018. Takemoto CK,Hodding JH, Kraus DM: Lexi-Comp’s Pediatric Dosage Handbook, ed 24, Hudson, OH, 2017–2018, Lexi-Comp. Trissel LA: Handbook of Injectable Drugs, ed 19, Bethesda, MD, 2016, American Society of Health-System Pharmacists. ILLUSTRATION CREDITS Kee JL, Hayes ER, McCuiston LE, editors: Pharmacology: A Nursing Process Approach, ed 7,Philadelphia, 2012, Saunders. vii NEWLY APPROVED MEDICATIONS Abacavir/dolutegravir/ lamivudine (Triumeq) A combination drug for treatment of HIV-1 infection. Abemaciclib (Verzenio) A kinase inhibitor for advanced breast cancer Acalabrutinib (Calquence) A kinase inhibitor for mantle cell lymphoma Angiotensin II (Giapreza) An IVvasoconstrictor to increase dangerously low blood pressure due to sepsis/shock Apalutamide (Er

Nursing drug handbook pdf free download In this post we have shared an overview and download link of Nurse's Drug Handbook 2021 PDF. The Drug Guide for nurses & other clinicians is always dependable, always up to date The thoroughly updated Nurse's Drug Handbook 2021. You must have this book on your study table if want to learn nursing .